Filing Details

Accession Number:
0001209191-16-146978
Form Type:
4
Zero Holdings:
No
Publication Time:
2016-10-26 16:15:45
Reporting Period:
2016-10-24
Filing Date:
2016-10-26
Accepted Time:
2016-10-26 16:15:45
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1674416 Crispr Therapeutics Ag CRSP Pharmaceutical Preparations (2834) DE
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
816284 Celgene Corp /De/ 86 Morris Avenue
Summit NJ 07901
No No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2016-10-24 4,034,830 $0.00 4,034,830 No 4 C Direct
Common Stock Acquisiton 2016-10-24 800,150 $14.00 4,834,980 No 4 P Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 C Direct
No 4 P Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Shares Series B Preferred Shares Disposition 2016-10-24 4,034,830 $0.00 4,034,830 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 2016-10-24 No 4 C Direct
Footnotes
  1. These securities converted on a one-for-one basis into shares of the Issuer's Common Stock upon the closing of the Issuer's initial public offering.
  2. These securities are held of record by Celgene Alpine Investment Co. III, LLC, an indirectly wholly-owned subsidiary of Celgene Corporation ("Celgene"). Celgene may be deemed to have voting and investment power over these securities and as a result may be deemed to have beneficial ownership over such securities.
  3. Celgene disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that Celgene is a beneficial owner of such securities for the purpose of Section 16 and the Exchange Act, or for any other purpose.
  4. These securities were convertible at any time on a one-for-one basis into shares of the Issuer's Common Stock at the holder's election and automatically upon the closing of the Issuer's initial public offering. These securities do not have an expiration date.